

PEER REVIEW HISTORY

BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (<http://bmjopen.bmj.com/site/about/resources/checklist.pdf>) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.

ARTICLE DETAILS

TITLE (PROVISIONAL)	Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study: INTERACT MESO.
AUTHORS	van Kooten, Job; Dietz, Michelle; Guchelaar, Niels; Brandt-Kerkhof, Alexandra; Koolen, Stijn; Burger, Jacobus; Mathijssen, Ron; Verhoef, Cornelis; Aerts, Joachim; Madsen, Eva

VERSION 1 – REVIEW

REVIEWER	Sammartino, Paolo Umberto I Policlinico di Roma, Pietro Valdoni
REVIEW RETURNED	10-Apr-2022

GENERAL COMMENTS	Interesting paper. Two remarks. First probably a different analysis is envisaged according histological evaluation Epithelioid, Biphasic, Sarcomatoid. Furthermore, as a second aspect it could be interesting to associate a PIPAC procedure (like induction therapy) with cisplatin at the moment of PAC inserting.
-------------------------	---

REVIEWER	Ihemelandu, Chukwuemeka Washington Cancer Institute
REVIEW RETURNED	17-Apr-2022

GENERAL COMMENTS	I commend the authors on their efforts I do have two comments: 1.) pg8 line 50, under study population, are we to understand that all types of peritoneal mesothelioma including the sarcomatoid histology are being included 2.) pg 13 line 20 under follow-up. I would suggest including that the RECIST criteria will be used to evaluate response
-------------------------	--

VERSION 1 – AUTHOR RESPONSE

Reviewer: 1

Dr. Paolo Sammartino, Umberto I Policlinico di Roma Comments to the Author:

Interesting paper. Two remarks. First probably a different analysis is envisaged according histological evaluation Epithelioid, Biphasic, Sarcomatoid. Furthermore, as a second aspect it could be interesting to associate a PIPAC procedure (like induction therapy) with cisplatin at the moment of PAC inserting.

Thank you very much for your comments. Regarding the first comment: the analysis will be the same for the different subtypes as the objectives of the study are to determine the MTD and the safety and feasibility of treatment with intraperitoneal paclitaxel monotherapy. We do not expect the histological

subtype to affect this outcome measures. In a future trial in which the efficacy of this treatment will be determined, this will indeed be relevant.

Regarding the second comment: thank you for this suggestion. As the current trial is a phase I trial, with the determination of the MTD as primary objective, the addition of a second intervention might affect the results. Especially since this is not a standard, ore proven effective treatment in the current patient population. Therefore, we will not add a PIPAC procedure at the PAC placement.

Reviewer: 2

Dr. Chukwuemeka Ihemelandu, Washington Cancer Institute Comments to the Author:

I commend the authors on their efforts

I do have two comments:

1.) pg8 line 50, under study population, are we to understand that all types of peritoneal mesothelioma including the sarcomatoid histology are being included

Thank you very much for your comments. It is correct that all histological subtypes of malignant peritoneal mesothelioma will be included.

2.) pg 13 line 20 under follow-up. I would suggest including that the RECIST criteria will be used to evaluate response

Thank you for pointing this out. We have added this to the manuscript.

VERSION 2 – REVIEW

REVIEWER	Sammartino, Paolo Umberto I Policlinico di Roma, Pietro Valdoni
REVIEW RETURNED	05-Jun-2022

GENERAL COMMENTS	Perfect paper for me no problem for publication.
-------------------------	--

REVIEWER	Ihemelandu, Chukwuemeka Washington Cancer Institute
REVIEW RETURNED	08-Jun-2022

GENERAL COMMENTS	Thank you for the effort being made to improve our understanding of the treatment of this disease
-------------------------	---